1. Home
  2. Analysis
  3. Pomalyst
  4. Mometasone-furoate

Pomalyst and Mometasone furoate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among 28 people who take Pomalyst and Mometasone furoate. Common interactions include malaise among females, and back pain among males.

The phase IV clinical study analyzes what interactions people who take Pomalyst and Mometasone furoate have. It is created by eHealthMe based on reports from the FDA, and is updated regularly. You may use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 700+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 01, 2023

28 people who take Pomalyst and Mometasone furoate together, and have interactions are studied.

What is Pomalyst?

Pomalyst has active ingredients of pomalidomide. Currently, eHealthMe is studying from 73,890 Pomalyst users.

What is Mometasone furoate?

Mometasone furoate has active ingredients of mometasone furoate. It is used in asthma. Currently, eHealthMe is studying from 10,212 Mometasone furoate users.

Number of Pomalyst and Mometasone furoate reports submitted per year:

Pomalyst and Mometasone furoate drug interactions.

Common Pomalyst and Mometasone Furoate drug interactions by gender *:

female:

  1. Malaise
  2. Pneumonia
  3. Drug ineffective
  4. Laryngitis
  5. Constipation
  6. Dyspnoea
  7. Fatigue
  8. Neutropenia
  9. Throat cancer
  10. Vocal cord paralysis

male:

  1. Back pain
  2. Fatigue
  3. Blood glucose increased
  4. Hypoaesthesia
  5. Jaw fracture
  6. Muscle spasms
  7. Muscular weakness
  8. T-lymphocyte count decreased
  9. White blood cell count decreased
  10. Adverse drug reaction

Common Pomalyst and Mometasone Furoate drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Adverse drug reaction

50-59:

n/a

60+:

  1. Fatigue
  2. Malaise
  3. Mouth ulceration
  4. Muscle spasms
  5. Pain
  6. Palmar-plantar erythrodysaesthesia syndrome
  7. Paraesthesia
  8. Plasma cell myeloma
  9. Rash
  10. Skin disorder

Common conditions people have *:

  1. Multiple Myeloma (cancer of the plasma cells): 25 people, 89.29%

* Approximation only. Some reports may have incomplete information.

Do you take Pomalyst and Mometasone furoate?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Drug side effects by duration, gender and age:

Common Pomalyst drug interactions:

Browse interactions between Pomalyst and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Mometasone furoate drug interactions:

Browse interactions between Mometasone furoate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on pomalidomide and mometasone furoate (the active ingredients of Pomalyst and Mometasone furoate, respectively), and Pomalyst and Mometasone furoate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Pomalyst and Mometasone furoate.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 700+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2023 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.